Clinical features and survival outcomes in patients with multiple myeloma: Analysis of web-based data from the korean myeloma registry

Seok Jin Kim; Kihyun Kim; Byung Soo Kim; Deog Yeon Jo; Hye Jin Kang; Jin Seok Kim; Yeung Chul Mun; Chul Soo Kim; Sang Kyun Sohn; Hyeon Seok Eom; Jae Yong Kwak; Hyeok Shim; Hwi Joong Yoon; Jong Youl Jin; Chang Ki Min; Hyunchoon Shin; Jong Ho Won; Je Jung Lee; Jung Hye Kwon; Young Don Joo; Young Rok Do; Sung Hyun Kim; Sukjoong Oh; Cheolwon Suh; Junglim Lee; Sung Soo Yoon; Min Kyoung Kim; Soo Mee Bang; Hun Mo Ryoo; Bong Seog Kim; Hawk Kim; Hyo Jung Kim; Yang Soo Kim; Chong Won Park; Gyeong Won Lee; Ho Jin Shin; Seong Kyu Park; Joon Seong Park; Ho Young Kim; Dong Soon Lee; Jae Hoon Lee

doi:10.1159/000253027

Clinical features and survival outcomes in patients with multiple myeloma: Analysis of web-based data from the korean myeloma registry

Seok Jin Kim, Kihyun Kim, Byung Soo Kim, Deog Yeon Jo, Hye Jin Kang, Jin Seok Kim, Yeung Chul Mun, Chul Soo Kim, Sang Kyun Sohn, Hyeon Seok Eom, Jae Yong Kwak, Hyeok Shim, Hwi Joong Yoon, Jong Youl Jin, Chang Ki Min, Hyunchoon Shin, Jong Ho Won, Je Jung Lee, Jung Hye Kwon, Young Don JooYoung Rok Do, Sung Hyun Kim, Sukjoong Oh, Cheolwon Suh, Junglim Lee, Sung Soo Yoon, Min Kyoung Kim, Soo Mee Bang, Hun Mo Ryoo, Bong Seog Kim, Hawk Kim, Hyo Jung Kim, Yang Soo Kim, Chong Won Park, Gyeong Won Lee, Ho Jin Shin, Seong Kyu Park, Joon Seong Park, Ho Young Kim, Dong Soon Lee, Jae Hoon Lee

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

Aim: The Korean Multiple Myeloma Working Party performed a nationwide registration of multiple myeloma patients via a web-based data bank system. Methods: We retrospectively analyzed registered data from 3,209 patients since 1999. Results: The median overall survival (OS) was 50.13 months (95% confidence interval: 46.20-54.06 months). Patients ≤40 years demonstrated a longer OS than patients >65 years of age (median OS 71.13 vs. 36.73 months, p < 0.001). Patients who received novel agents at any time during their treatments showed a longer OS than patients who did not (median OS 42.23 vs. 55.50 months, p < 0.001). Response to treatment was associated with OS, with tandem autologous stem cell transplantation (SCT) producing longer OS than single autologous SCT. Conclusions: We demonstrated associations between survival outcomes and treatment modalities as well as baseline disease characteristics in a registry of multiple myeloma patients using a web-based data analysis.

Original language	English
Pages (from-to)	200-210
Number of pages	11
Journal	Acta Haematologica
Volume	122
Issue number	4
DOIs	https://doi.org/10.1159/000253027
State	Published - Nov 2009

Keywords

Multiple myeloma
Stem cell transplantation, autologous
Stem cell transplantation, tandem autologous

Access to Document

10.1159/000253027

Cite this

Kim, S. J., Kim, K., Kim, B. S., Jo, D. Y., Kang, H. J., Kim, J. S., Mun, Y. C., Kim, C. S., Sohn, S. K., Eom, H. S., Kwak, J. Y., Shim, H., Yoon, H. J., Jin, J. Y., Min, C. K., Shin, H., Won, J. H., Lee, J. J., Kwon, J. H., ... Lee, J. H. (2009). Clinical features and survival outcomes in patients with multiple myeloma: Analysis of web-based data from the korean myeloma registry. Acta Haematologica, 122(4), 200-210. https://doi.org/10.1159/000253027

@article{6df00a348aac47fba2b09a4db67d7635,

title = "Clinical features and survival outcomes in patients with multiple myeloma: Analysis of web-based data from the korean myeloma registry",

abstract = "Aim: The Korean Multiple Myeloma Working Party performed a nationwide registration of multiple myeloma patients via a web-based data bank system. Methods: We retrospectively analyzed registered data from 3,209 patients since 1999. Results: The median overall survival (OS) was 50.13 months (95% confidence interval: 46.20-54.06 months). Patients ≤40 years demonstrated a longer OS than patients >65 years of age (median OS 71.13 vs. 36.73 months, p < 0.001). Patients who received novel agents at any time during their treatments showed a longer OS than patients who did not (median OS 42.23 vs. 55.50 months, p < 0.001). Response to treatment was associated with OS, with tandem autologous stem cell transplantation (SCT) producing longer OS than single autologous SCT. Conclusions: We demonstrated associations between survival outcomes and treatment modalities as well as baseline disease characteristics in a registry of multiple myeloma patients using a web-based data analysis.",

keywords = "Multiple myeloma, Stem cell transplantation, autologous, Stem cell transplantation, tandem autologous",

author = "Kim, {Seok Jin} and Kihyun Kim and Kim, {Byung Soo} and Jo, {Deog Yeon} and Kang, {Hye Jin} and Kim, {Jin Seok} and Mun, {Yeung Chul} and Kim, {Chul Soo} and Sohn, {Sang Kyun} and Eom, {Hyeon Seok} and Kwak, {Jae Yong} and Hyeok Shim and Yoon, {Hwi Joong} and Jin, {Jong Youl} and Min, {Chang Ki} and Hyunchoon Shin and Won, {Jong Ho} and Lee, {Je Jung} and Kwon, {Jung Hye} and Joo, {Young Don} and Do, {Young Rok} and Kim, {Sung Hyun} and Sukjoong Oh and Cheolwon Suh and Junglim Lee and Yoon, {Sung Soo} and Kim, {Min Kyoung} and Bang, {Soo Mee} and Ryoo, {Hun Mo} and Kim, {Bong Seog} and Hawk Kim and Kim, {Hyo Jung} and Kim, {Yang Soo} and Park, {Chong Won} and Lee, {Gyeong Won} and Shin, {Ho Jin} and Park, {Seong Kyu} and Park, {Joon Seong} and Kim, {Ho Young} and Lee, {Dong Soon} and Lee, {Jae Hoon}",

year = "2009",

month = nov,

doi = "10.1159/000253027",

language = "English",

volume = "122",

pages = "200--210",

journal = "Acta Haematologica",

issn = "0001-5792",

publisher = "S. Karger AG",

number = "4",

}

Kim, SJ, Kim, K, Kim, BS, Jo, DY, Kang, HJ, Kim, JS, Mun, YC, Kim, CS, Sohn, SK, Eom, HS, Kwak, JY, Shim, H, Yoon, HJ, Jin, JY, Min, CK, Shin, H, Won, JH, Lee, JJ, Kwon, JH, Joo, YD, Do, YR, Kim, SH, Oh, S, Suh, C, Lee, J, Yoon, SS, Kim, MK, Bang, SM, Ryoo, HM, Kim, BS, Kim, H, Kim, HJ, Kim, YS, Park, CW, Lee, GW, Shin, HJ, Park, SK, Park, JS, Kim, HY, Lee, DS & Lee, JH 2009, 'Clinical features and survival outcomes in patients with multiple myeloma: Analysis of web-based data from the korean myeloma registry', Acta Haematologica, vol. 122, no. 4, pp. 200-210. https://doi.org/10.1159/000253027

TY - JOUR

T1 - Clinical features and survival outcomes in patients with multiple myeloma

T2 - Analysis of web-based data from the korean myeloma registry

AU - Kim, Seok Jin

AU - Kim, Kihyun

AU - Kim, Byung Soo

AU - Jo, Deog Yeon

AU - Kang, Hye Jin

AU - Kim, Jin Seok

AU - Mun, Yeung Chul

AU - Kim, Chul Soo

AU - Sohn, Sang Kyun

AU - Eom, Hyeon Seok

AU - Kwak, Jae Yong

AU - Shim, Hyeok

AU - Yoon, Hwi Joong

AU - Jin, Jong Youl

AU - Min, Chang Ki

AU - Shin, Hyunchoon

AU - Won, Jong Ho

AU - Lee, Je Jung

AU - Kwon, Jung Hye

AU - Joo, Young Don

AU - Do, Young Rok

AU - Kim, Sung Hyun

AU - Oh, Sukjoong

AU - Suh, Cheolwon

AU - Lee, Junglim

AU - Yoon, Sung Soo

AU - Kim, Min Kyoung

AU - Bang, Soo Mee

AU - Ryoo, Hun Mo

AU - Kim, Bong Seog

AU - Kim, Hawk

AU - Kim, Hyo Jung

AU - Kim, Yang Soo

AU - Park, Chong Won

AU - Lee, Gyeong Won

AU - Shin, Ho Jin

AU - Park, Seong Kyu

AU - Park, Joon Seong

AU - Kim, Ho Young

AU - Lee, Dong Soon

AU - Lee, Jae Hoon

PY - 2009/11

Y1 - 2009/11

N2 - Aim: The Korean Multiple Myeloma Working Party performed a nationwide registration of multiple myeloma patients via a web-based data bank system. Methods: We retrospectively analyzed registered data from 3,209 patients since 1999. Results: The median overall survival (OS) was 50.13 months (95% confidence interval: 46.20-54.06 months). Patients ≤40 years demonstrated a longer OS than patients >65 years of age (median OS 71.13 vs. 36.73 months, p < 0.001). Patients who received novel agents at any time during their treatments showed a longer OS than patients who did not (median OS 42.23 vs. 55.50 months, p < 0.001). Response to treatment was associated with OS, with tandem autologous stem cell transplantation (SCT) producing longer OS than single autologous SCT. Conclusions: We demonstrated associations between survival outcomes and treatment modalities as well as baseline disease characteristics in a registry of multiple myeloma patients using a web-based data analysis.

AB - Aim: The Korean Multiple Myeloma Working Party performed a nationwide registration of multiple myeloma patients via a web-based data bank system. Methods: We retrospectively analyzed registered data from 3,209 patients since 1999. Results: The median overall survival (OS) was 50.13 months (95% confidence interval: 46.20-54.06 months). Patients ≤40 years demonstrated a longer OS than patients >65 years of age (median OS 71.13 vs. 36.73 months, p < 0.001). Patients who received novel agents at any time during their treatments showed a longer OS than patients who did not (median OS 42.23 vs. 55.50 months, p < 0.001). Response to treatment was associated with OS, with tandem autologous stem cell transplantation (SCT) producing longer OS than single autologous SCT. Conclusions: We demonstrated associations between survival outcomes and treatment modalities as well as baseline disease characteristics in a registry of multiple myeloma patients using a web-based data analysis.

KW - Multiple myeloma

KW - Stem cell transplantation, autologous

KW - Stem cell transplantation, tandem autologous

UR - http://www.scopus.com/inward/record.url?scp=70350543697&partnerID=8YFLogxK

U2 - 10.1159/000253027

DO - 10.1159/000253027

M3 - Article

C2 - 19887776

AN - SCOPUS:70350543697

SN - 0001-5792

VL - 122

SP - 200

EP - 210

JO - Acta Haematologica

JF - Acta Haematologica

IS - 4

ER -

Clinical features and survival outcomes in patients with multiple myeloma: Analysis of web-based data from the korean myeloma registry

Abstract

Keywords

Access to Document

Fingerprint

Cite this